Dezhan Healthcare Company Limited (SHE:000813)

China · Delayed Price · Currency is CNY

3.320

+0.030 (0.91%)

Jul 29, 2026, 3:04 PM CST

-15.52% (1Y)

Market Cap	6.96B -16.2%
Revenue (ttm)	396.16M -12.8%
Net Income	-357.73M
EPS	-0.17
Shares Out	2.10B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,222,673
Open	3.300
Previous Close	3.290
Day's Range	3.270 - 3.350
52-Week Range	2.750 - 5.260
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Dezhan Healthcare Company

Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. The company offers atorvastatin calcium tablets, amlodipine-atorvastatin calcium tablets, warfarin sodium tablets, trimetazidine hydrochloride tablets, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, hydroxyurea tablets, colchicine tablet, and oseltamivir phosphate capsules. It also involved in the provision o... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1980

Employees 1,067

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 000813

Full Company Profile

Financial Performance

In 2025, Dezhan Healthcare Company's revenue was 396.81 million, a decrease of -14.94% compared to the previous year's 466.49 million. Losses were -345.42 million, 1592.2% more than in 2024.

Financial Statements